{
  "id": "61f5f377882a024a10000016",
  "type": "list",
  "question": "What is the use of pegcetacoplan?",
  "ideal_answer": "Pegcetacoplan is promising for paroxysmal nocturnal haemoglobinuria and Geographic Atrophy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34147650",
    "http://www.ncbi.nlm.nih.gov/pubmed/31474439",
    "http://www.ncbi.nlm.nih.gov/pubmed/33675755",
    "http://www.ncbi.nlm.nih.gov/pubmed/34482398",
    "http://www.ncbi.nlm.nih.gov/pubmed/33711380",
    "http://www.ncbi.nlm.nih.gov/pubmed/33464651",
    "http://www.ncbi.nlm.nih.gov/pubmed/34342834",
    "http://www.ncbi.nlm.nih.gov/pubmed/33730455",
    "http://www.ncbi.nlm.nih.gov/pubmed/34445916"
  ],
  "snippets": [
    {
      "text": "Addressing some of the unmet needs, a long-acting C5 inhibitor, ravulizumab, and a C3 inhibitor, pegcetacoplan have been also now approved with PNH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approval of pegcetacoplan (Empaveli), a PEGylated compstatin-based C3 therapeutic, as a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) marks a milestone in the history of complement drug discovery. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34147650",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pegcetacoplan treatment significantly controlled GA progression even after accounting for these risk factors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33675755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33730455",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33730455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31474439",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Local C3 inhibition with pegcetacoplan resulted in statistically significant reductions in the growth of GA compared with sham treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31474439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pegcetacoplan is the first C3-targeted paroxysmal nocturnal haemoglobinuria (PNH) therapy to be approved (in May 2021) in the USA, where it is indicated for the treatment of adults with PNH, including those switching from C5 inhibitor therapy with eculizumab and ravulizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34342834",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ONCLUSIONS: Results suggest that among patients previously treated with eculizumab, clinical, hematological, and quality of life endpoints were better for patients who received the C3 complement inhibitor pegcetacoplan vs. patients who received ravulizumab, a C5 complement inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34445916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pegcetacoplan (APL-2), a PEGylated C3 inhibitor, has the potential to provide more complete hemolysis control in patients with PNH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33464651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal nocturnal hemoglobinuria (PNH) previously treated with eculizumab using matching-adjusted indirect comparison methodology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34445916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Beyond PNH, complement inhibition has also shown efficacy and safety in cold agglutinin disease (CAD), primarily with the C1s inhibitor of the classical complement pathway, sutimlimab, but also with pegcetacoplan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approval of pegcetacoplan (Empaveli), a PEGylated compstatin-based C3 therapeutic, as a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) marks a milestone in the history of complement drug discovery. Alm",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34147650",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33711380",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This article summarizes the milestones in the development of pegcetacoplan leading to this first approval for the treatment of adults with PNH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34342834",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33711380",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The FDA approval of pegcetacoplan (Empaveli), a PEGylated compstatin-based C3 therapeutic, as a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) marks a milestone in the history of complement drug discovery.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34147650",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Geographic Atrophy, paroxysmal nocturnal haemoglobinuria"
}